Introduction Executive Summary Nonalcoholic Steatohepatitis: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Nonalcoholic Steatohepatitis – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • Nonalcoholic Steatohepatitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends Nonalcoholic Steatohepatitis Collaboration Deals • Company-Company Collaborations (Licensing / Partnering) Analysis • Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) • Comparative Analysis Resmetirom: Madrigal Pharmaceuticals • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis ALS-L1023: AngioLab • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) • Comparative Analysis CB4211: CohBar • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Preclinical and Discovery Stage Products • Comparative Analysis ALG-055009: Aligos Therapeutics • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Nonalcoholic Steatohepatitis Key Companies Nonalcoholic Steatohepatitis Key Products Nonalcoholic Steatohepatitis- Unmet Needs Nonalcoholic Steatohepatitis- Market Drivers and Barriers Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion Nonalcoholic Steatohepatitis Analyst Views Nonalcoholic Steatohepatitis Key Companies Appendix

Table 1 Total Products for Nonalcoholic Steatohepatitis Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Novo Nordisk • Madrigal Pharmaceuticals • PharmaKing • Cirius Therapeutics • Inventiva Pharma • Galmed Pharmaceuticals • AbbVie • Galectin Therapeutics • Viking Therapeutics • Sagimet Biosciences • Novartis • Hepion Pharmaceuticals • Celgene • Boston Pharmaceuticals • Bristol-Myers Squibb • NGM Biopharmaceuticals • Boehringer Ingelheim • Axcella Health • Corcept Therapeutics • TaiwanJ Pharmaceuticals • AngioLab • Oramed • Can-Fite Biopharma • Mitsubishi Tanabe Pharma • MediciNova • Merck Sharp & Dohme • Metacrine • MedImmune • Lipocine • Chemomab Therapeutics • Afimmune • NorthSea Therapeutics • Rivus Pharmaceuticals • HighTide Biopharma • Hanmi Pharmaceutical • ENYO Pharma • Histogen • Akero Therapeutics • Enanta Pharmaceuticals • Gilead Sciences • Ionis Pharmaceuticals • Eli Lilly and Company • Terns Pharmaceuticals • Sinew Pharma • Poxel • CytoDyn • Future Medicine • 89bio Ltd. • HK inno.N • Arrowhead Pharmaceuticals • Promethera Biosciences • Enanta Pharmaceuticals